Şizofrenide Sürdürüm Tedavisi
Özet
Şizofreni, erken erişkinlikte başlayan ve yaşam boyu süren, bilişsel, negatif ve pozitif belirtilerle seyreden psikiyatrik bir hastalıktır. Antipsikotik ilaçlar tedavinin temelini oluştursa da, iki yıl içinde %25, beş yıl içinde ise %40-60 oranında nüks görülebilmektedir. Sürdürüm tedavisinde temel hedefler; remisyonun korunması, yinelemelerin önlenmesi ve yaşam kalitesinin artırılmasıdır. Tedavi planlamasında, akut dönemde fayda sağlayan ilacın en düşük etkin dozda kullanımı ve farmakolojik yöntemlerin psikososyal yaklaşımlarla desteklenmesi önerilmektedir. Tedavi uyumsuzluğu ve içgörü eksikliği gibi durumlarda uzun etkili antipsikotikler tercih edilebilir. İlk ataktan sonra sürdürüm tedavisinin 1-2 yıl, çoklu ataklarda ise en az 5 yıl sürmesi gerektiği konusunda fikir birliği vardır. İlaç kesme veya doz azaltma kararı, sadece pozitif belirtilerin düzelmesine değil, hastanın işlevselliğine ve nüks riskine göre çok yönlü değerlendirilmelidir. Günümüzde modern ruh sağlığı anlayışı, hastaların kendi ortamlarında toplum temelli merkezler ve bakım verenlerin desteğiyle tedavisini amaçlamaktadır.
Schizophrenia is a lifelong psychiatric disorder characterized by cognitive, negative, and positive symptoms that typically onset in early adulthood. Although antipsychotic medications form the cornerstone of treatment, relapse rates reach 25% within two years and 40-60% within five years. The primary goals of maintenance treatment are sustaining remission, preventing relapses, and improving quality of life. In treatment planning, continuing the drug that provided benefit during the acute phase at the lowest effective dose is recommended, alongside supporting pharmacological methods with psychosocial approaches. Long-acting antipsychotics may be preferred in cases of treatment non-compliance or lack of insight. There is a consensus that maintenance therapy should last 1-2 years after the first episode and at least 5 years for multiple episodes. Decisions regarding dose reduction or discontinuation must be comprehensively evaluated based on the patient's functionality and relapse risk, rather than just the resolution of positive symptoms. Today, the modern approach to mental health aims to continue treatment within patients' own environments through community-based centers and caregiver support.
Referanslar
Ertuğrul, A. (2010) Şizofreninin Nörobiyolojisi, Temel Psikofarmakoloji, 1: 354, Ankara.
Köroğlu, E. (1996) Şizofreni, Psikiyatri 7, 239-272.
Kaplan, H., Sadock, B. (1998) Kaplan and Sadock’s Synopsis of Psychiatry, 8: 375-456.
Sağlık Bakanlığı. Türkiye Hastalık Yükü Çalışması 2004. Ankara: Türkiye Cumhuriyeti Sağlık Bakanlığı; 2006
Arieti, S. (2008) Understanding And Helping The Schizoprenic. (Çeviri: Eti A. Bir Şizofreni Anlamak) 2. Baskı. İstanbul: Doruk Yayımcılık.
Çekmeci S. (2005) Bir Akıl Hastalığı Olarak: Şizofreni. İçinde: Güveli M (ed). Psikiyatri Penceresi. İstanbul: Hayat Yayıncılık, s:137-141
Üçok, A. (2008) Şizofreni Nedir? İstanbul: Janssen – Cilag Yayınları.
Mc Gorry PD, Hartmann JA, Spooner R, et al. Beyond the “at risk mentalstate” concept: transitioning to transdiagnostic psychiatry. World Psychiatry 2018;17:133–142
Remington GI, Adams ME. Depot neuroleptics. Schizophrenia: Exploring the Spectrum of Psychosis, Edited by RJ Ancill, S Holliday, J Higenbotham, New York, Wiley, 1994.
Schooler NR. Relapse prevention and recovery in the treatment of schizophrenia. J Clin Psychiatry 2006; 67(Suppl.5): 19-23.
JH Jenkins, E Carpenter-Song, The new paradigm of recovery from schizophrenia: cultural conundrums of improvement without cure, Culture, Medicine and Psychiatry,2005, 379–413.
Jaaskelainen E, Juola P, Hirvonen N et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull 2013;39:1296–1306.
Sadock BJ, Sadock VA. (2003) Synopsis of Psychiatry, Behavioral Sciences / Clinical Psychiatry, Lippincott Williams & Wilkins, ( Ninth edit.) p:375-402, New York.
American Psychiatric Association. The Practice Guideline for the Treatment of Patients with Schizophrenia (undergoing copy editing version): American Psychiatric Association; 2019.
Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2013;14:2–44.
Türkiye Psikiyatri Derneği Şizofreni ve Diğer Psikotik Bozukluklar Çalışma Birimi. Şizofrenide Sürdürüm Tedavisi. In: Ucok A, Soygur H, editors. Şizofreni Tedavi Kılavuzu. Ankara: Türkiye Psikiyatri Derneği; 2010. p.13–22.
Scholler NR, Keith SJ, Severe JB, et al. Relapse and rehospitalization during maintenance treatment of schizophrenia: the effects of dose reduction and family treatment. Arch Gen Psychiatry 1997;54:453-63.
Barnes TRE. Evidence based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011;25:567–620.
Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia - a shortversion for primarycare. Int J Psychiatry Clin Pract 2017;21:82–90.
SIGN. Management of schizophrenia–A national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; 2013.
Falkai P, Wobrock T, Lieberman J, et al. Task Force on Treatment Guide. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia. World J Biol Psychiatry 2009;7:5–40.
Leucht S, Heres S, Kissling W, et al. Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol 2011;14:269–284.
NICE. Psychosis and schizophrenia in adults: prevention and management. United Kingdom: National Institute for Health and Care Excellence (NICE); 2014.
Kirli, Umut ve Alptekin, Köksal. Akut ve İdame Aşamasında Şizofreninin Farmakoterapisi. Nöropsikiyatri Arşivi 58.Ek 1 (2021): S17.
Canadian Psychiatric Association. Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry 2005;50(13 Suppl 1):7S– 57S.
Remington G, Addington D, Honer W, et al. Guidelines for the Pharmacotherapy of Schizophrenia in Adults. Can J Psychiatry 2017;62:604–616.
Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;36:71–93.
Working Group of the Clinical Practice Guideline for Schizophrenia and Incipient Psychotic Disorder. Barcelona: Catalan Agency for Health Technology Assessment and Research; 2009.
Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Aust N Z J Psychiatry 2005;39:1–30
Abidi S, Mian I, Garcia-Ortega I, et al. Canadian Guidelines for the Pharmacological Treatment Of Schizophrenia Spectrum and Other Psychotic Disorders in Children and Youth. Can J Psychiatry 2017;62:635–647.
American Psychiatric A. Practice guidelines for the treatment of patients with schizophrenia, Am J Psychiatriy, 2004;161: 3-57.
Baldessarini RJ, Cohen BM, Teicher MH Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses, Arch Gen Psychiatry 1988;45(1): 79-91.
Tenhula WN, Bellack AS. Schizophrenia and Other Psychotic Disorders, Comprehensive Textbook of Psychiatry, Library of Congress Cataloging-in-Publication Data, 2009; 9: 1556-1572.
Nasrallah HA, Smeltzer DJ. (2005). Şizofreni Güncel Tanı ve Tedavi Kitabı, 1:209-210, Ankara: AND Yayıncılık,
